EUVIMEDEUVIMED entdecken
Vergleichsstudie

Combined dupilumab with immunotherapy is more effective than dupilumab alone in children with moderate-to-severe atopic dermatitis

Qi-Qing Ye, Ying Liang, Yun-Yan Li, Li-Fen Yang, Li Pan, Qin-Tai Yang, Pei-Ying Feng, Zhuang-Gui Chen, Ping-Ping Zhang

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.115143 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Qi-Qing Ye und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Sun Yat-sen University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Dupilumab for patients with moderate-to-severe atopic dermatitis (AD) does not maintain efficacy after discontinuation, while subcutaneous immunotherapy (SCIT) with enduring efficacy may be useful as a complementary treatment to dupilumab. OBJECTIVE: This study aimed to compare the efficacy between dupilumab alone and SCIT as an adjunctive treatment in children with moderate-to-severe AD, and assess the long-term clinical and immunological outcomes of this combination approach. METHODS: In this real-world study, patients with moderate-to-severe AD, who had IgE-mediated sensitization to house dust mites with varying degrees of respiratory symptoms, were divided into two treatment groups: Dupilumab + SCIT (n = 22) and dupilumab alone (n = 24). The efficacy assessments include immunological indicators and clinical scores related to AD and respiratory symptoms, measured in five visits, throughout the 30-month treatment period. RESULTS: By month 12, both groups demonstrated significant improvements in all clinical assessments (p < .001). By month 18, the Dupilumab + SCIT group continued the improvement trend (p < .001). In contrast, all clinical scores, except the combined symptom and medication score (CSMS), increased in the dupilumab alone group (p < .001). At the end of the treatment (month 30), the Dupilumab + SCIT group demonstrated significant improvement over the dupilumab alone group in all clinical outcomes (p < .001). Similar trends were observed in Immunological indicators, with significant improvements in the Dupilumab + SCIT Group over the Dupilumab Group (p < .001). CONCLUSIONS: The addition of subcutaneous immunotherapy (SCIT) to dupilumab in children with moderate-to-severe AD has been shown to maintain substantial efficacy over a longer period than dupilumab alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedImmunotherapyHumansChildMaleFemaleTreatment OutcomeChild, PreschoolSeverity of Illness IndexAdolescentImmunoglobulin EInjections, SubcutaneousPyroglyphidaeAnimals

Stichwörter der Autor:innen

Atopic dermatitisChildrenDupilumabReal-world studySubcutaneous immunotherapy

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedImmunoglobulin E

Autor:innen und Institutionen

  • Department of Pediatrics, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Department of Allergy, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Department of Pediatrics, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; Department of Allergy, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Electronic address: chenzhua…
  • Department of Pediatrics, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; Department of Allergy, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Electronic address: zhpingp@…

Förderung

  • Sun Yat-sen University

Zitieren

APA

Ye, Q. Q., Liang, Y., Li, Y. Y., Yang, L. F., Pan, L., Yang, Q. T., Feng, P. Y., Chen, Z. G., & Zhang, P. P. (2025). Combined dupilumab with immunotherapy is more effective than dupilumab alone in children with moderate-to-severe atopic dermatitis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115143

Vancouver

Ye QQ, Liang Y, Li YY, Yang LF, Pan L, Yang QT, et al. Combined dupilumab with immunotherapy is more effective than dupilumab alone in children with moderate-to-severe atopic dermatitis. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115143

BibTeX
@article{Ye2025,
  author = {Ye, Qi-Qing and Liang, Ying and Li, Yun-Yan and Yang, Li-Fen and Pan, Li and Yang, Qin-Tai and Feng, Pei-Ying and Chen, Zhuang-Gui and Zhang, Ping-Ping},
  title = {Combined dupilumab with immunotherapy is more effective than dupilumab alone in children with moderate-to-severe atopic dermatitis},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.115143}
}
Kostenlos starten →